Logotype for ASP Isotopes Inc

ASP Isotopes (ASPI) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ASP Isotopes Inc

Q3 2026 earnings summary

16 Nov, 2026

Executive summary

  • Q3 revenue rose to $5.1M from $1.3M YoY, while operating loss widened to $40.5M from $15.0M; 9M revenue was $14.4M and operating loss $99.6M.

  • Results include newly consolidated Renergen, Numed and ECNP; enriched-isotope sales had not begun by September 30, 2026.

  • Liquidity was $201.7M in cash and cash equivalents; management expects available resources to cover operating and capital needs for more than 12 months from issuance.

Financial highlights

  • Q3 revenue was $5.124M, up from $1.271M YoY; product revenue was $5.124M and collaboration revenue was nil.

  • 9M revenue was $14.427M, up from $3.571M YoY, including $13.627M product revenue and $0.800M TerraPower collaboration revenue.

  • Q3 gross profit was $0.793M vs. $0.242M; operating loss was $40.515M vs. $14.987M. 9M gross profit was $3.940M vs. $1.141M; operating loss was $99.598M vs. $34.908M.

  • Net loss attributable to shareholders was $30.371M in Q3 and $70.833M for 9M; attributable loss per share was $0.21 and $0.55, respectively.

  • Q3 other income included an $11.250M convertible-note extinguishment gain; 9M other income was $9.022M, versus $61.817M of other expense in 2025.

Outlook and guidance

  • Initial Si-28 shipments are targeted for Q4 2026; initial C-14 shipments may occur in 2027, dependent on customer feedstock timing and quality; Yb-176 shipments are targeted for 2027.

  • Management expects Helium and LNG margins to improve in 2027 as production volumes rise and fixed costs are absorbed over a larger production base.

  • Phase 2 of the Virginia Gas Project is estimated to cost more than $1.0B; a conditional DFC commitment of up to $500M was extended to July 1, 2029, while definitive financing remains unexecuted.

  • Management expects R&D and SG&A to increase substantially as isotope development, commercialization and public-company requirements expand.

  • The ENDRA merger is anticipated in Q4 2026 or, subject to an extension, Q1 2027; closing depends on shareholder approval, financing and other conditions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ASP Isotopes